Effect of iron and vitamin C co-supplementation in hyperthyroidism patients

Effect of iron and vitamin C co-supplementation on thyroid hormones, hematological parameters, oxidative stress, inflammation, and quality of life in hyperthyroidism patients

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20090822002365N27

Enrollment

Registered

2022-03-04

Start date

2022-02-20

Completion date

Unknown

Last updated

2022-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Hyperthyroidism. Condition 2: Iron deficiency anemia. Thyrotoxicosis [hyperthyroidism] Iron deficiency anemia

Interventions

Intervention 1: Intervention group: 40 men and women with hyperthyroidism receive two tablets of 27 mg of iron supplement and 100 mg of vitamin C daily for 8 weeks each. Intervention 2: Control group:

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Men and women over 18 years of age with newly diagnosed hyperthyroidism Body mass index18.5-30 kg / m2 Hemoglobin level less than 12.7 g / dl for women and less than 13 g / dl for men Start a medication program No autoimmune diseases and chronic diseases such as diabetes, hypertension, kidney, liver, gallbladder, thyroid, parathyroid, bone, gastrointestinal and hyperphosphatemia disorders No infectious diseases, malignancies and severe bleeding in the last 2 months No thalassemia and other blood disorders Do not use hormonal drugs, anticonvulsants, cholesterol and fat lowering drugs, antacids, blood thinners, and laxatives. Do not take iron and vitamin C supplements during the last month No history of other thyroid disorders In the case of women, the absence of abnormal and irregular menstrual cycles No pregnancy and lactation Willingness to cooperate

Exclusion criteria

Exclusion criteria: Having any acute illness Changes in medications Non-regular use of supplements and acceptance rate less than 90% Migration Exclusion based on personal preference of participants

Design outcomes

Primary

Measure	Time frame
Thyroid stimulating hormone. Timepoint: Before intervention and 8 weeks after intervention. Method of measurement: The level of TSH in serum is with ELISA method.	—

Secondary

Measure	Time frame
High-sensitive C-reactive protein (hs-CRP). Timepoint: At the baseline and after 8 weeks of intervention. Method of measurement: The level of Hs-CRP in serum is with ELISA method.;Free thyroxine hormone levels. Timepoint: At the baseline and after 8 weeks of intervention. Method of measurement: The level of FT4 in serum with ELISA method.;Free triiodothyronine Hormone Levels. Timepoint: At the baseline and after 8 weeks of intervention. Method of measurement: The level of FT3 in serum with ELISA method.;Malondialdehyde. Timepoint: At the baseline and after 8 weeks of intervention. Method of measurement: The level of MDA in serum with ELISA method.;Total antioxidant capacity. Timepoint: At the baseline and after 8 weeks of intervention. Method of measurement: The level of TAC in serum with ELISA method.;Hemoglobin. Timepoint: At the baseline and after 8 weeks of intervention. Method of measurement: Using an automated Hematology analyzer.;Red blood cell. Timepoint: At the baseline and after 8 weeks of intervention. Method of measurement: Using an automated Hematology analyzer.;Mean corpuscular volume. Timepoint: At the baseline and after 8 weeks of intervention. Method of measurement: Using an automated Hematology analyzer.	—

Measure

Time frame

High-sensitive C-reactive protein (hs-CRP). Timepoint: At the baseline and after 8 weeks of intervention. Method of measurement: The level of Hs-CRP in serum is with ELISA method.;Free thyroxine hormone levels. Timepoint: At the baseline and after 8 weeks of intervention. Method of measurement: The level of FT4 in serum with ELISA method.;Free triiodothyronine Hormone Levels. Timepoint: At the baseline and after 8 weeks of intervention. Method of measurement: The level of FT3 in serum with ELISA method.;Malondialdehyde. Timepoint: At the baseline and after 8 weeks of intervention. Method of measurement: The level of MDA in serum with ELISA method.;Total antioxidant capacity. Timepoint: At the baseline and after 8 weeks of intervention. Method of measurement: The level of TAC in serum with ELISA method.;Hemoglobin. Timepoint: At the baseline and after 8 weeks of intervention. Method of measurement: Using an automated Hematology analyzer.;Red blood cell. Timepoint: At the baseline and after 8 weeks of intervention. Method of measurement: Using an automated Hematology analyzer.;Mean corpuscular volume. Timepoint: At the baseline and after 8 weeks of intervention. Method of measurement: Using an automated Hematology analyzer.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Reza Vafa

Iran University of Medical Sciences

vafa.m@iums.ac.ir+98 21 8670 4743

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026